Completed PHASE2 INTERVENTIONAL 4-arm NCT01303224

Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D) (IRIS-2)

Double-blind, Randomised, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Effect of Oral Ibodutant in Irritable Bowel Syndrome With Diarrhoea (IBS-D).

Sponsor: Menarini Group

Conditions Irritable Bowel Syndrome With Diarrhea

Interventions Ibodutant Placebo

Updated 8 times since 2017 Last updated: Sep 22, 2015 Started: Oct 31, 2010 Primary completion: May 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Irritable Bowel Syndrome With Diarrhea and is currently completed. Menarini Group leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Menarini Group

Data source: Menarini Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Badalona, Spain , Ballerup Municipality, Denmark , Barcelona, Spain , Berlin, Germany , Bialystok, Poland , Bydgoszcz, Poland , Cologne, Germany , Como, Italy , Dresden, Germany and 48 more locations